Superluminal Medicines secures $60M for AI-driven obesity drug
Boston-based Superluminal Medicines, which uses AI and machine learning for drug discovery, closed a $60 million Series B round on September 3, 2026. The financing was oversubscribed, indicating strong investor interest in its obesity-focused pipeline.
Sources: unite.ai
“The oversubscribed round reflects growing investor confidence in AI-driven drug discovery, particularly for obesity—a market expanding beyond GLP-1 therapies.”
Read the original reporting
This is a short summary. The outlets below did the reporting.
This brief was drafted automatically from the sources above and published under our editorial policy. Spotted an error? Tell us.